Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eli Lilly reports ‘solid’ financial figures

Eli Lilly reports ‘solid’ financial figures

28th July 2008

Eli Lilly has announced its second-quarter financials for the 2008 fiscal year, with the company reporting “solid” results for the period.

During the quarter, the firm generated revenues of $5.150 billion (2.593 billion pounds), an 11 per cent rise on the same time last year.

Net income rose from $655.6 million in the comparable quarter in 2007 to $958.8 million, while earnings per share rose from $0.61 to $0.88.

Research and development costs were $951.5 million, equal to 18 per cent of the total sales figure.

Administrative, marketing and selling expenses rose 12 per cent for the quarter to $1.7 billion as a result of foreign exchange rates, higher marketing expenses and an increase in litigation-related expenses.

John Lechleiter, president and chief executive officer of Eli Lilly, said: “Lilly continued to deliver solid financial results in the second quarter, including double-digit growth in sales and earnings.”

He added newer products in the company’s portfolio, such as Alimta (pemetrexed), Cialis (tadalafil) and Cymbalta (duloxetine), continued to perform well.

Earlier this month, Eli Lilly expressed its commitment to the enhanced code from Pharmaceuticals Research and Manufacturers of America regarding interactions with healthcare professionals.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.